Download PDF
Dtsch Med Wochenschr 2021; 146(20): 1353-1359
DOI: 10.1055/a-1578-6802
Review

Stellenwert der ASS-Therapie in der kardio- und zerebrovaskulären Prävention

Aspirin in primary prevention of cardiovascular and cerebrovascular diseases
Natig Gassanov
1   Medizinische Klinik II, Klinikum Idar-Oberstein, Idar-Oberstein
,
Martin Eicke
2   Klinik für Neurologie, Klinikum Idar-Oberstein, Idar-Oberstein
,
Fikret Er
3   Klinik I für Innere Medizin, Klinikum Gütersloh, Gütersloh
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Acetylsalicylsäure (ASS), eines der am meisten verwendeten Medikamente weltweit, spielt als Thrombozytenaggregationshemmer eine bedeutende Rolle bei der Behandlung und Sekundärprophylaxe vieler vaskulärer Erkrankungen. Dagegen ist die primärprophylaktische Indikation umstritten. Nach der neuesten Evidenz wird der Einsatz von ASS zunehmend kritisch bei Patienten ohne bestehende atherosklerotische Erkrankungen bewertet. Zwar senkt die Substanz die ischämischen Ereignisse, dies geht allerdings mit einem erhöhten Blutungsrisiko einher, sodass in der Summe kein relevanter klinischer Vorteil übrigbleibt. Deswegen wird das Mittel bei Patienten ohne nachgewiesene kardio- bzw. zerebrovaskuläre Erkrankung generell nicht empfohlen.

Abstract

Acetylsalicylic acid (aspirin) is one of the most used medications worldwide. The antithrombotic agent acts mainly through inhibition of cyclooxygenase-1 and consequently thromboxane A2 synthesis, causing an irreversible suppression of platelet function. Despite of its proven benefit in the treatment and secondary prevention of atherosclerotic diseases, its use for the primary prevention remains controversial due to an unclear balance between the benefits and risks of aspirin. Moreover, the recent evidence indicates that the risk of major bleeding outweighs the potential to reduce ischemic events in patients without atherosclerotic diseases, thus, precluding the general use of aspirin for the primary prevention.

Schlüsselwörter

Acetylsalicylsäure - Prävention - Atherosklerose

Key words

acetylsalicylic acid - prevention - atherosklerosis


Publication History

Article published online:
13 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res 2014; 12: 147-154
    CrossrefPubMedSearch in Google Scholar
  • 2 Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011; 123: 768-778
    CrossrefPubMedSearch in Google Scholar
  • 3 Craven LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 1950; 4: 95
    PubMedSearch in Google Scholar
  • 4 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231: 235-237
    CrossrefPubMedSearch in Google Scholar
  • 5 Chandrasekharan NV, Dai H, Roos KL. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926-13931
    CrossrefPubMedSearch in Google Scholar
  • 6 FitzGerald GA, Oates JA, Hawiger J. et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
    CrossrefPubMedSearch in Google Scholar
  • 7 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632
    CrossrefPubMedSearch in Google Scholar
  • 8 Heavey DJ, Barrow SE, Hickling NE. et al. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Nature 1985; 318: 186-188
    CrossrefPubMedSearch in Google Scholar
  • 9 Steering Committee of the Physiciansʼ Health Study Research G. Final report on the aspirin component of the ongoing Physiciansʼ Health Study. N Engl J Med 1989; 321: 129-135
    CrossrefPubMedSearch in Google Scholar
  • 10 McNeil JJ, Nelson MR, Woods RL. et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379: 1519-1528
    CrossrefPubMedSearch in Google Scholar
  • 11 Johnston SC, Easton JD, Farrant M. et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018; 379: 215-225
    CrossrefPubMedSearch in Google Scholar
  • 12 Gaziano JM, Brotons C, Coppolecchia R. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046
    CrossrefPubMedSearch in Google Scholar
  • 13 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323
    CrossrefPubMedSearch in Google Scholar
  • 14 Group ASC, Bowman L, Mafham M. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539
    CrossrefPubMedSearch in Google Scholar
  • 15 Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA 2019; 321: 277-287
    CrossrefPubMedSearch in Google Scholar
  • 16 Lewis HD, Davis Jr JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403
    CrossrefPubMedSearch in Google Scholar
  • 17 Cairns JA, Gent M, Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369-1375
    CrossrefPubMedSearch in Google Scholar
  • 18 Theroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111
    CrossrefPubMedSearch in Google Scholar
  • 19 Juul-Moller S, Edvardsson N, Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425
    CrossrefPubMedSearch in Google Scholar
  • 20 Patrono C, Coller B, Dalen JE. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S-488S
    CrossrefPubMedSearch in Google Scholar
  • 21 Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587-1593
    CrossrefPubMedSearch in Google Scholar
  • 22 Jones WS, Mulder H, Wruck LM. et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med 2021;
    CrossrefPubMedSearch in Google Scholar
  • 23 Sandercock PA, Counsell C, Tseng MC. et al. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2014; CD000029
    CrossrefPubMedSearch in Google Scholar
  • 24 Antithrombotic Trialists C, Baigent C, Blackwell L. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
    CrossrefPubMedSearch in Google Scholar
  • 25 Rothwell PM, Algra A, Chen Z. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365-375
    CrossrefPubMedSearch in Google Scholar
  • 26 Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762
    CrossrefPubMedSearch in Google Scholar
  • 27 [Anonym]. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Councilʼs General Practice Research Framework. Lancet 1998; 351: 233-241
    CrossrefPubMedSearch in Google Scholar
  • 28 de Gaetano G. Collaborative Group of the Primary Prevention P. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95
    CrossrefPubMedSearch in Google Scholar
  • 29 Cote R, Battista RN, Abrahamowicz M. et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 1995; 123: 649-655
    CrossrefPubMedSearch in Google Scholar
  • 30 Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40: e573-e583
    CrossrefPubMedSearch in Google Scholar
  • 31 Halliday A, Harrison M, Hayter E. et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376: 1074-1084
    CrossrefPubMedSearch in Google Scholar
  • 32 Patrono C, Garcia Rodriguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383
    CrossrefPubMedSearch in Google Scholar
  • 33 Eckstein HH, Kuhnl A, Berkefeld J. et al. [Webinar for S3 guideline „diagnosis, treatment, and aftercare of extracranial carotid stenosis“]. Chirurg 2021; 92: 383-384
    CrossrefPubMedSearch in Google Scholar
  • 34 Judge C, Ruttledge S, Murphy R. et al. Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. Int J Stroke 2020; 15: 9-17
    CrossrefPubMedSearch in Google Scholar
  • 35 Sacco M, Pellegrini F, Roncaglioni MC. et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272
    CrossrefPubMedSearch in Google Scholar
  • 36 Ridker PM, Manson JE, Gaziano JM. et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839
    CrossrefPubMedSearch in Google Scholar